Personalis Inc

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Personalis Inc excels in Q4 earnings, eyes growth through strategic focus

Personalis Inc's Q4 2022 earnings call highlighted strong financial performance, strategic focus on MRD, and guidance for 2023 amidst market challenges and opportunities.
The company's strengths in partnerships, product innovation, and financial management position it well for future growth and success in a competitive landscape.
While facing challenges in sample delivery, margin expectations, and operational changes, Personalis Inc is poised to leverage opportunities in partnerships, product launches, and market expansion.
Navigating the evolving landscape with resilience and adaptability, Personalis Inc aims to drive growth, profitability, and innovation in the coming year.

Personalis Inc reports strong Q1 revenue growth and oncology progress

Personalis Inc's Q1 2023 performance showcased revenue growth and progress in oncology.
The company aims to launch NeXT Personal for clinical use by Q4 2023, targeting cancer diagnostics.
Challenges include managing expenses, net loss, and ensuring efficient cash usage for financial goals.

Personalis Inc reports Q2 revenue growth, eyes strong collaborations

Personalis Inc is strategically positioned for growth in oncology with NeXT Personal and key collaborations, despite facing financial challenges and revenue fluctuations.
The company's strong balance sheet and prudent expense management offer financial stability and a 2-year cash runway, supporting future growth opportunities.
Legal battles and variability in data publication speed present challenges, but active engagement in scientific advancement and partnerships drive credibility and revenue potential.
Overall, Personalis is navigating a complex landscape with a focus on innovation, financial sustainability, and scientific credibility to drive future success.

Personalis Inc reports strong Q3 growth and strategic partnerships

Personalis Inc's Q3 performance reflects growth in key revenue segments and strategic advancements in cancer research collaborations and product launches.
While facing challenges in net losses and reimbursement coverage, the company's focus on partnerships, operational efficiency, and revenue growth presents opportunities for market expansion.
With a strong cash position, reduced OpEx, and plans for revenue growth, Personalis Inc is poised for strategic growth and market capture in the genomics industry.

Personalis Inc (PSNL) reports robust Q4 performance and strategic growth plans

Personalis Inc (PSNL) delivered strong financial performance in Q4 2023, with revenue growth, improved margins, and cost efficiency measures.
The company's focus on strategic collaborations, strong financial position, and targeted market approach position it well for future growth.
Challenges in revenue guidance, regulatory hurdles, and managing partnerships require careful navigation, but opportunities in key cancer areas offer significant growth potential.

Personalis Inc surpasses revenue targets, eyes MRD test leadership

Personalis Inc demonstrated strong financial performance in Q1 2024, exceeding revenue guidance.
The company's focus on MRD testing and strong IP protections positions it well for future growth.
Challenges lie in balancing test adoption with reimbursement considerations for sustained growth.
Opportunities exist to solidify NeXT Personal's position in clinical diagnostics through strategic planning.

Personalis Inc reports robust Q2 earnings, eyes growth opportunities

Personalis Inc delivered strong financial performance in Q2 2024, driven by revenue growth and strategic initiatives.
The company's focus on MRD testing, partnerships, and innovative strategies position them for future growth.
While challenges like market competition and cash management exist, opportunities in diversification and partnerships are promising.

Personalis Inc reports robust Q3 revenue growth and strategic expansion

Personalis Inc's Q3 performance reflects strong revenue growth and financial stability, underpinned by a focus on innovation and market expansion.
While facing challenges in achieving reimbursement and managing expenses, the company's strategic initiatives position it well for future growth and profitability.
With a clear roadmap for revenue expansion and a commitment to financial efficiency, Personalis Inc is poised to capitalize on growth opportunities in the MRD testing market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life.

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024. “Personalis is excited to present data showing ou.

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company's NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay. NeXT Personal is designed to help detect minimal residual disease (MRD), monitor therapy response, and identify recurrence with high analytical sensitivity and accuracy, enhancing the decision-making process and ultimately impr.

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights. Recent Business Highlights Obtained final Medicare coverage determination for its NeXT Dx® comprehensive tumor genomic profiling test, providing access for the 66 million Medicare and Medicare Advantage beneficiaries Entered into a strategic.

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 f.

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

FREMONT, Calif. & SAN DIEGO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote's cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. “We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health's bloo.

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation's 66 million Medicare and Medicare Advantage beneficiaries. Matching patients to their optimal cancer therapy requires a testing platform that can accurately report a broader range of clinically actionable g.

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance Preliminary total company revenue is estimated to be $19.7 million in the fourth quarter of 2023, an increase of 18% compared with $16.7 million in the fourth quarter of 2022 Preliminary revenue from pharma tests, enter.

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company's staff. By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually. This action, along with the recently announced Tempus collaboration, is expected to extend the cash position of the company into 2026. “Continuin.

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

FREMONT, Calif. & CHICAGO--(BUSINESS WIRE)--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal® Dx, Personalis' whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is a leap forward in tumor-informe.

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Personalis, Inc. (NASDAQ:PSNL ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Research and Development Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Mark Massaro - VTIG Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call.

Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights. Third Quarter and Recent Highlights Achieved third quarter revenue of $18.2 million, representing an increase of 23% over the same period of the prior year Presented compelling clinical data from the collaboration with the TRACERx consortium for lung cancer.

Personalis Reports Third Quarter 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. Designed to help oncologists detect cancer recurrence earlier and aid in treatment decision-making, NeXT Personal Dx is poised to reshape the.

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 844-826-3035 for dom.

Personalis to Announce Third Quarter 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management. The Personalis NeXT Personal cancer assay, created to detect and monitor residual and recurrent disease (MRD), demonstrated significantly improved detection rates for early-stag.

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress, on October 21 in Madrid, Spain. Presentation #LBA55 Title: “An ultra-sensitive and specific ctD.

Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held seni.

Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Personalis is a small-cap stock specializing in cancer genomics, with an advanced cancer diagnostics platform. The company reported significant losses in Q2 earnings but maintains a robust financial standing and expects future revenue growth. Personalis has partnerships and collaborations in place to drive revenue growth and is well-positioned in the growing field of personalized cancer diagnostics and therapies.

Personalis: Collaborations Should Ignite Growth Narrative

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton New York. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradig.

Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

Personalis, Inc. (NASDAQ:PSNL ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Tejas Savant - Morgan Stanley Mark Massaro - BTIG Swayampakula Ramakanth - H.C. Wainwright Dan Brennan - Cowen Mike Matson - Needham & Company Operator Greetings and welcome to Personalis Second Quarter 2023 Earnings Conference Call.

Personalis, Inc. (PSNL) Q2 2023 Earnings Call Transcript

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with National Cancer Center Hospital East and Ono Pharmaceutical Co. Ltd to perform exploratory biomarker analysis using highly sensitive and comprehensive genomic tests from Personalis to better predict immunot.

Personalis Reports Second Quarter 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for dome.

Personalis to Announce Second Quarter 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced that the company has filed a second patent infringement suit against Foresight Diagnostics Inc. Personalis is seeking injunctive relief and monetary damages. This suit brings the total number of patents that Personalis alleges Foresight Diagnostics has infringed to seven. The additional suit, filed in the U.S. District Court for the District of Colorado, alleges that Foresight improperly based its solid tumor mini.

Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics

FREMONT, Calif.--(BUSINESS WIRE)--Dr. Kenneth J. Widder Joins Personalis Board of Directors.

News for Personalis Inc Stock (PSNL)